1411 results about "Inflammatory disorder" patented technology

Provided herein are compounds of Formula (I), or a pharmaceutically acceptable form thereof, and pharmaceutical compositions comprising the same. Also provided herein methods of modulating the activity of cellular targets by administering to a subject a compound of Formula (I), or a pharmaceutically acceptable form thereof. Further provided herein are methods of treating cancer, fibrotic diseases, and inflammatory diseases by administering to a subject a compound of or a pharmaceutically acceptable form thereof.

A compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof wherein X-Y is -NHSO2- or -SO2NH-; R1 is H, CN or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H and halo; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, halo, SO2-alkyl, optionally substituted heteroaryl, SO2NR14R15, CONR10R11 and alkyl; R8 is selected from H, alkyl, haloalkyl and halo; R9 is H or halo; and R10, R11, R12, R14, and R15 are H or alkyl; R13 is selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; and m is 0-3. The compounds of formula (I) modulate ERAP1 (endoplasmic reticulum aminopeptidase 1) and are for use in treating proliferative, immune or inflammatory disorders, particularly cancer or leukemia. The compounds of formula (I) stimulate a neo-antigen directed immune response in the subject. A method for producing an antigen-presenting cell which presents a neo-antigen using compounds of formula (I) is disclosed. An immunogenic composition comprising an antigen-presenting cell is also disclosed. Exemplified compounds include 4-cyclopropyl-3-(N-(2-(morpholin-3-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and / or Multiple Sclerosis.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and / or Multiple Sclerosis.

Methods and apparatuses (e.g., devices and systems) for vagus nerve stimulation, including (but not limited to) sub-diaphragmatic vagus nerve stimulation. In particular, the methods and apparatuses described herein may be used to stimulate the posterior sub-diaphragmatic vagus nerve to treat inflammation and / or inflammatory disorders. The implantable microstimulators described herein may be leadless and batteryless.

The invention discloses a lysosome targeted chimera based on Sortilin and application thereof. The lysosome targeted chimera comprises a ligand molecule of a lysosome targeted receptor and a ligand molecule of a targeted protein to be degraded, wherein the ligand molecule and the ligand molecule are connected through a linker; the lysosome targeting receptor is Sortilin, and the ligand molecule of the lysosome targeting receptor is a polypeptide targeting the Sortilin; the protein to be degraded is membrane protein or extracellular protein. Furthermore, the polypeptide of the targeted Sortilin is connected with an enzyme response sequence and an integrin receptor targeting sequence. According to the invention, the Sortilin-combined ligand neurotensin is functionally coupled with the neutralizing antibody or polypeptide of overexpression protein in targeted tumor or inflammatory diseases, and the Sortilin-combined ligand neurotensin has obvious treatment gain in malignant solid tumor and psoriasis models. The discovery promotes the transformation potential of the lysosome participating in the biological agent, and provides a dual strategy for realizing accurate degradation through receptor recruitment and microenvironment induction.

The invention discloses lactobacillus plantarum capable of relieving enteritis and toxicity of polystyrene nano-plastics, and the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) NO.31420. The lactobacillus plantarum can be used for relieving enteritis and toxicity of polystyrene nano-plastics. The strain is obtained by separating and purifying baby feces, and can grow on an MRS culture medium, and the bacterial colony is round, off-white, smooth and opaque. Experiments show that the lactobacillus plantarum can effectively adsorb PS-NPs, promote the PS-NPs to be discharged along with excrement, reduce accumulation of the PS-NPs in organs, and significantly reduce toxicity and inflammatory response of organs such as liver and kidney of mice. In addition, the strain can repair the intestinal barrier function, regulate liver metabolism and relieve enteritis symptoms. The invention further provides a probiotic preparation containing the strain, and the probiotic preparation can be prepared into granules, capsules, tablets or oral liquid and the like and is used for preventing or treating intestinal injury and inflammatory diseases caused by PS-NPs. The strain is safe and efficient, and has a wide application prospect.

To provide a pharmaceutical agent that has STAT6 inhibitory activity and is effective for the treatment of allergic diseases and inflammatory diseases such as atopic dermatitis.SOLUTION: A pharmaceutical agent contains, as an active ingredient, a compound represented by the general formula (I) in the figure or a pharmaceutically acceptable salt thereof, which has STAT6 inhibitory activity.SELECTED DRAWING: None

The disclosure includes compounds of Formula (I)wherein Q1, Q2, Q3, W, X, Y, Z1, m, n, Warhead, R1, R2, R3, R4, and R5, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.

The invention relates to a probiotic agent for regulating an intestinal environment and an application of the probiotic agent. The bacterial strains in the probiotic agent for regulating the intestinal environment comprise a Bifidobacterium animalis subsp. Lactis C-1 bacterial strain and a Lactobacillus gasseri CKCC 1913 bacterial strain, and the bacterial strains in the probiotic agent for regulating the intestinal environment comprise a lactobacillus plantarum subsp. Lactis C-1 bacterial strain and a lactobacillus gasseri CKCC 1913 bacterial strain, a lactobacillus plantarum subsp. Lactis CKCC 1913 bacterial strain, a lactobacillus plantarum subsp. Lactis CKCC 1913 bacterial strain and a lactobacillus plantarum subsp. Lactis CKCC 1913 bacterial strain. A synergistic interaction relationship exists between the two bacteria, so that the intestinal micro-ecological environment can be regulated, the intestinal injury can be relieved and the intestinal barrier function can be improved by reducing the level of inflammatory factors, balancing the content of gastrointestinal regulatory peptides, promoting intestinal peristalsis and other action mechanisms. Therefore, the probiotic agent is suitable for preparing a preparation with the efficacy of preventing, improving or treating constipation and other inflammatory diseases.

The present application discloses substituted polycyclic heterocycles compound of Formula (I), pharmaceutically acceptable salt and / or solvate and pharmaceutical compositions thereof useful in the treatment of proliferative disease or condition characterized by a dysregulation of the RAS-ERK pathway such as neoplasm disease or disorder, inflammatory disease or immune system disorder.

Provided herein are elastin-like polypeptides, endosomal escape peptides, and compounds comprising an elastin-like polypeptide chemically or recombinantly conjugated to one or more endosomal escape peptides. Also provided herein are compositions comprising a compound provided herein and an agent, methods of delivering an agent, and methods of treating or preventing a disease (e.g., a cardiovascular disease, a lung or respiratory disease, a musculoskeletal disease, a hematological disease, an immune disorder, an infectious disease, a genetic disease, cancer, a neurological disease, a psychiatric disorder, a metabolic disorder, or an inflammatory disease).

The present disclosure relates to bicyclic heterocycles of Formula (I), and pharmaceutical compositions of the same, that are modulators, antagonists, or inhibitors of the G protein-coupled receptor MRGPRX2 and are useful in the treatment of MRGPRX2 dependent conditions such as inflammatory diseases.

The invention discloses a preparation method of an anti-human TNF (Tumor Necrosis Factor) alpha egg yolk antibody. Relates to the technical field of biomedicine. The invention provides a sequence of the fusion protein, an egg yolk antibody and application. The fusion protein provided by the invention is constructed by combining a human TNF alpha sequence and an IgY Fc fragment, and efficient production is realized through a pichia pastoris expression system. The specific egg yolk antibody aiming at the human TNF alpha protein is generated by adopting an immune laying hen technology. The anti-TNF alpha egg yolk antibody prepared by the invention is expected to be converted into various clinical application forms by virtue of an innovative preparation process and excellent affinity, occurrence and development of inflammatory diseases are effectively inhibited and relieved, and a new biomedical solution is provided for diagnosis and treatment of the inflammatory diseases.

Provided herein are methods and compositions comprising a set of paired peptides comprising a first bacterial effector polypeptide or fragment thereof linked to a second bacterial effector polypeptide or fragment thereof. The paired peptides can be linked to a protein transduction domain. The compositions can be formulated as pharmaceuticals. The compositions are useful for the treatment of inflammatory disorders.

A novel Akkermansia muciniphila EB-AMDK39 strain (KCTC 13765BP) and composition containing the novel strain or extracellular vesicles (EVs) derived from the strain are disclosed. The composition can be in a form of pharmaceutical, food, or veterinary composition. The compositions are useful to preventing or treating cancer or inflammatory disease, or ameliorating cancer or inflammatory disease.

The invention relates to an aromatic soluble polymer microneedle as well as a preparation method and application thereof. The preparation method comprises the following steps: adding a zinc acetate hexahydrate aqueous solution and a Tris buffer solution into a eugenol-curcumin mixed ethanol solution to obtain self-assembled carrier-free nanoparticles containing eugenol and curcumin; and dissolving the nano-particles in a soluble hyaluronic acid solution, drying in a microneedle mold, and demolding to obtain the aromatic soluble polymer microneedle. The structure of the aromatic soluble polymer microneedle is that self-assembled carrier-free nanoparticles are wrapped in a soluble hyaluronic acid microneedle. Compared with the prior art, the aromatic soluble polymer microneedle prepared by the invention can overcome skin barrier and quickly absorb moisture and dissolve so as to promote the transdermal absorption effect of active substances; a perfume delivery system is constructed by using the soluble polymer microneedle, so that the biocompatibility is improved, the slow release control capability of the perfume can be effectively enhanced, and a new path is opened up for clinical application of inflammatory diseases.

Provided herein are a fusion protein comprising an interleukin-22 domain and an albumin binding domain, and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an inflammatory disease.

The present invention relates to the pharmaceutical compositions of lectin proteins and its use for the prevention, treatment and cure of inflammation, including inflammatory disease. The invention specifically relates to the pharmaceutical compositions for topical application comprising lectin proteins and its use for prevention, treatment and cure of inflammation due to chemotherapy and / or radiotherapy. The lectin may comprise an amino acid sequence having sequence of SEQ ID NO: 1 or at least 70% homology to SEQ ID NO: 1.

Described herein are antibodies, or antigen binding fragments thereof, that bind OX40L and IL- 13 in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and IL- 13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-OX40L and anti-IL-13 antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder (e.g., associated with elevated levels of OX40L and / or IL- 13). Also described herein are compositions and combinations comprising an antibody or an antigen binding region that binds OX40L, an antibody or antigen binding region that binds IL- 13, and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

The invention provides an application of a pentacyclic triterpenoid compound targeting hydroxyl steroid 17-beta dehydrogenase 4. The pentacyclic triterpenoid compound can effectively relieve or treat central nervous system diseases (inflammatory diseases), including central nervous system degenerative diseases or chronic central inflammatory diseases. The pentacyclic triterpenoid compound can maintain the structural stability or activity of hydroxysteroid 17-beta dehydrogenase and maintain the stability or activity of peroxisome, thereby relieving or treating central nervous inflammation. The pentacyclic triterpenoid compound can target hydroxysteroid 17-beta dehydrogenase 4, inhibit neuroglial cell excessive activation related neuroinflammation, relieve neuron damage or death speed and improve a central nervous system cell metabolism microenvironment.

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.

The disclosure includes compounds of any one of Formulae (0)-(5), (11)-(24), (A)-(E), and (1)-(V) comprising an E3 ubiquitin ligase binding moiety that binds an E3 ubiquitin ligase, as described herein. Also disclosed pharmaceutical compositions comprising compounds, and a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.

The invention discloses a cyclic IL-10mRNA nano preparation as well as a preparation method and application thereof, and belongs to the technical field of biology. The annular IL-10mRNA nano preparation is prepared by the following method: 1, synthesizing chemically modified annular IL-10mRNA in vitro, and 2, preparing the annular IL-10mRNA nano preparation capable of being delivered in vivo by a self-assembly method. The annular IL-10mRNA can regulate immune cells in synovial membranes of articular cavities and inhibit articular cartilage injury, so that the effect of treating joint inflammatory diseases is achieved. The application has the advantages that the annular IL-10mRNA is successfully delivered into the joint cavity with the joint inflammatory disease through the nano system, and the inflammation environment in the joint cavity with the joint inflammatory disease is adjusted, so that the development of inflammation is inhibited; the cyclic IL-10 promotes cartilage repair so as to improve the disease progress of joint inflammatory diseases.

The invention belongs to the technical field of biotechnology and genetic engineering, and particularly relates to application of recombinant RASA3 in preparation of a medicine for preventing and treating viral pneumonia. The recombinant RASA3 is used for promoting autophagy degradation of a transcription factor CEBP / beta protein and reducing the expression level of the transcription factor CEBP / beta protein, so that generation of inflammatory factors such as IL-6 is reduced, and inflammatory damage caused by excessive antiviral innate immune response in the virus infection process is improved. The invention provides a novel treatment strategy for inflammatory diseases caused by RNA viruses such as influenza and respiratory syncytial virus infection.

The present invention discloses salts of a Compound 1:useful in the prophylaxis and / or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and / or disruption of cartilage homeostasis, congenital cartilage malformations, and / or diseases associated with hypersecretion of IL6 or interferons.

The invention belongs to the technical field of nano material synthesis, and particularly relates to baicalein-copper nano microgel as well as a preparation method and application thereof. According to the invention, copper ions and baicalein are coordinated to form nanowires, and the nanowires are coated with hyaluronic acid (HA) to prepare the nano microgel. The method is carried out at normal temperature, is simple in process and high in yield, and does not need toxic solvents; the obtained microgel has high stability (gastric acid resistance), targeted delivery (CD44 receptor mediation) and multiple biological activities (oxidation resistance and inflammation resistance). Animal experiments show that the pharmaceutical composition can significantly relieve ulcerative colitis, the dosage is as low as 5 mg / kg, the pharmaceutical composition is non-toxic, and a new strategy is provided for treatment of inflammatory diseases.